Snowball Digital helps ambitious start-ups, growth companies, and enterprises with Product Design, Product Development, and Product Growth. We design and build addictive products loved by the customers of our clients, by working as a team of experts across design, engineering, and marketing. We simply love designing, building, launching, and growing products.

Homely leverer boligalarm tilknyttet døgnåpen, FG-godkjent alarmstasjon. Med en fast lav månedspris og en moderne og fleksibel smarthus-plattform er Homely en boligalarm for folk flest. Alle sikkerhetsprodukter styres fra Homely-appen. Homely har inngått avtale med Storebrand forsikring som tilbyr og anbefaler løsningen til sine kunder.

We improve the way the shipping industry works and communicates. The whole industry is currently bogged down with unstructured emails and ship data.We have built a great ship database, and have a growing and happy customer base just from this. But we are not done. We are building communication tools on top of this, massively increasing the number of users we can help out!

Apotek 1 er Norges største apotekkjede og vi er i stadig vekst. Hos oss jobber ca. 3500 dedikerte medarbeidere, og vi er også landets største farmasøytiske arbeidsgiver. Vi har en stolt kultur med klare ambisjoner om alltid å leve opp til vårt slagord 'Vår kunnskap - din trygghet' i våre kundemøter. Kompetanse og kvalitet er kjernen for vår virksomhet, og derfor er faglig og personlig videreutvikling av våre medarbeidere helt sentralt i kjeden. I Apotek 1 er vi opptatt av å etterleve våre verdier som er: pålitelig, frisk, engasjert og nær. Vi bestreber at dette skal prege alle ansatte, alle beslutninger, alle handlinger og alle mål i selskapet. Apotek 1 Gruppen AS er eiet av den tyske Phoenix-gruppen. Servicekontor og distribusjonsenhet ligger på Lørenskog i Akershus. Vi er landets største leverandør av legemidler pakket i multidose, samt legemidler og tjenester til kommunehelsetjenesten, blant annet legemiddelgjennomganger.

Novelty Food was established to promote great-tasting gifts for the premium market. Our basic philosophy is to create products that are tempting enough for you to buy the first time, and tasty enough for you to want to buy again. Novelty Food er et utviklings-, salgs, og markedsselskap for premium produkter. Vi har en stabil og god salgsbase i Norge med salg til både Norgesgruppen, Sunkost og Tax Free butikkene. Vi har i tillegg flere internasjonale partnere – blant annet Disney World og EPCOT, hvor Grieg Suites er valgt som den norske sjokoladen for salg.

Bygg- og anleggsbransjen er en lite digitalisert bransje per dags dato. NAEVA setter fokus på mer enn digitalisering. Vi ønsker i tillegg å effektivisere og automatisere hverdagen.Ved å kombinere de beste menneskene med nyskapende teknologi og innovative løsninger, ønsker vi å skape fremtidens bygg- og anleggsbransje i dag. Vi har vårt utgangspunkt i bygg- og anleggsbransjen, men våre løsninger kan skreddersys de fleste bransjer og industrier.

Coleapri is a Norway based research and technology company. We seek inspiration from nature to create efficient technical solutions that are less harmful to the environment. The company has developed cutting-edge technologies in the field of  transportation of fluids, energy conversion and marine propulsion. The technology has a level of efficiency and competitive advantages well beyond anything currently achievable by conventional devices

UNISOT is a young Norwegian start-up company and is the first global Blockchain solution based on tight integration with Enterprise Resource Planning (ERP) systems, such as SAP and other major ERP and SCM systems. Its permissionless manner will allow unprecedented abilities for secure information exchange and secure information storage to companies and/or organizations all over the world. For the first time and with the help of the open, public blockchain, UNISOT can now offer access to a reliable and secure “Universal Source of Truth” that all parties can use to handle the challenges in today’s supply chain environment, such as increased globalization, faster pace of change, global traceability, information shortage, and settlement costs, to name a few. UNISOT is leveraging the very well-established ERP Business Processes with the trust, security, immutability, and tokenization that the Open Public Permissionless Blockchain technology provides.

People find going to the optician frustrating and it is something they tend to delay as long as possible. Pain points include complicated, non-transparent pricing, lack of understanding about lenses and the options available, and insecurity when choosing glasses. Our mission is to remove these pain points and provide a more relevant modern alternative to the traditional optician. Our vertical concept allows us to offer high-quality designer eyewear at affordable prices - enabling people to build a collection of eyewear to meet the needs of their individual lifestyles. We are currently generating 14 million Nok in sales per year through our 5 Kaibosh stores (Oslo, Bergen, Copenhagen, Frederiksberg & Aarhus), e-commerce operation, and wholesale distribution channels.

Misc Games is a game developer based in Stavanger – Norway, with several collaborators around the world. We make games for PC/Consoles. Misc Games aims at developing unique games for various niche markets. We treat developers like human beings and video games like art rather than toys. Everyone at Misc Games has a strong passionate for video games and that’s why we want to evolve the industry into something better. We want to develop games mostly for the more mature and educated gamers.

iO Data is here to help companies build their digital businesses. Only 33% of companies rate their level of digitalization as advanced today, but 70% expect they will get there by 2020¹. This transformation process will be critical for future success. Our core business is hosting, conversion, QC, and accessibility of Big Data. Bundled with Security Audits, Embedded Development, Destruction, Consultancy, and Innovation.

What is Between? The process of moving out of your home and into a new one can be one of the greatest stresses of life. To the average person, it’s an expensive and overwhelming process that involves listmaking, phone calls with real estate agents, taking time off from work, packing, heavy lifting, buying takeaway dinners, cleaning, and so on. Have you ever wondered why there’s no app that could help alleviate the pain points of moving? We have. That’s why we founded Between – Norway’s first moving platform. Between is a digital service that revolutionizes the moving process with technology, innovation and the ability to understand needs. To the average person, it means less stress and more control. To electrical and insurance companies, who each year lose thousands of customers due to address changes, it will lead to a lower churn rate and a higher return on investment. To real estate agents and developers, we will provide added value to a much smoother customer journey. What we have achieved We are a small group of entrepreneurs who have founded several successful businesses together. One of which is an online change of address service, a pilot company which has helped us research the moving market for the last two years – with over 50.000 registered customers in Norway and Sweden. Between is the next step. Not just for us, but for the millions of people out there who are about to begin a new life in a new home. We’re doing this because we know that if we can make moving easier, we will also make life easier.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

Yetz is a new distribution platform for product lines such as insurance, electricity, telecom, and finance. At launch, we will offer both insurance and power. We utilize strong incentives towards our customers and partners to share the concept, by giving them an affiliate commission. Monthly payment is based on the turnover of customers they have referred. Two fully owned sister companies Yetz Strøm og Yetz Forsikring.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.